RxDoctor Payments DataLook up a doctor →

Joshua Strauss, MD

Hematology & Oncology · Springfield, NJNPI 1699919597

Payments from drug & device makers

$739,181in general payments, 2019–2025

Across 1,245 payments — averaging $593.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$201K
  • Exelixis Inc.$180K
  • Pharmacosmos Therapeutics Inc.$125K
  • Amgen$64K
  • Beigene USA, Inc.$61K
  • Servier Pharmaceuticals LLC$36K
  • plus $73K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Incyte Corporation268$200,919
Exelixis Inc.212$179,997
Pharmacosmos Therapeutics Inc.147$125,224
Amgen88$63,924
Beigene USA, Inc.55$60,605
Servier Pharmaceuticals LLC42$35,521
Beone Medicines USA, Inc.13$23,812
Ipsen Biopharmaceuticals, Inc9$6,304
Genentech USA, Inc.16$5,817
AstraZeneca(2 entities)19$5,630
AbbVie32$5,333
Pfizer23$4,479
Gilead(2 entities)16$4,286
Sanofi6$3,711
Agios Pharmaceuticals, Inc.3$2,876
Jazz Pharmaceuticals Inc.3$2,127
Seagen Inc.6$1,301
Daiichi Sankyo Inc.12$812
Geron Corporation2$797
Astellas Pharma US Inc10$643
Novartis39$625
GSK10$610
Johnson & Johnson(2 entities)37$477
E.r. Squibb & Sons, L.L.C.32$475
Merck27$442
Sanofi-aventis U.S. LLC1$300
Mirati Therapeutics, Inc.15$246
Array Biopharma Inc9$157
Bristol Myers Squibb8$135
Takeda Pharmaceuticals U.S.A., Inc.6$121
Celltrion USA Inc.1$114
La Jolla Pharmaceutical Company1$97
Taiho Oncology, Inc.6$96
Foundation Medicine, Inc.4$86
Regeneron Healthcare Solutions, Inc.5$81
Lilly USA, LLC5$80
Bayer4$76
Eisai Inc.4$62
CTI Biopharma Corp.3$59
Sobi, Inc3$53
Sumitomo Pharma America, Inc.3$51
Global Blood Therapeutics, Inc.3$41
Acera Surgical, Inc.1$37
EMD Serono, Inc.2$34
Deciphera Pharmaceuticals Inc.2$32
Rigel Pharmaceuticals, Inc.2$29
Myovant Sciences Inc.2$29
Boehringer Ingelheim2$28
AVEO Pharmaceuticals, Inc.1$24
Lexicon Pharmaceuticals, Inc.2$23
Sirtex Medical Inc1$21
Spectrum Pharmaceuticals Inc.1$20
Secura Bio, Inc.1$19
Kyowa Kirin, Inc.1$19
W. L. Gore & Associates, Inc.1$18
Morphosys, US Inc.1$17
Karyopharm Therapeutics Inc.1$16
Janssen Scientific Affairs, LLC1$15
EUSA Pharma (US) LLC1$15
Genmab U.S., Inc.1$15

How this compares

$739,181 in reported general payments places this provider in the 90th percentile of 362 hematology & oncology providers in New Jersey.

See all hematology & oncology providers in New Jersey →

Medicare billing

Part B allowed, 2024
$190,294
Medicare patients
628
Services billed
2,460

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Springfield

See the full list for New Jersey →

Where these figures come from

Is this you, or does something look wrong? →